Physician profile
Patrick K Link
NPI 1992767164
$5,292.73
in general payments reported to CMS, 2019-2025
28 companies · $2,311 in 2025
The $2,311 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $545 · 2024: $2,437 · 2025: $2,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,203 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,202.73 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $923.55 | 2023-2025 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $842.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $470.53 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $457.41 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $313.33 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $293.58 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.54 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $184.36 | 2024-2025 | Auvelity |
| Medtronic, INC. | $182.83 | 2024-2025 | Linq II, Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $163.53 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Cvrx, INC. | $159.13 | 2024 | Barostim Neo System |
| Phathom Pharmaceuticals, INC. | $146.93 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $139.57 | 2023-2025 | |
| Exact Sciences Corporation | $137.60 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.11 | 2024-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $88.09 | 2024-2025 | Azstarys |
| Dexcom, INC. | $86.72 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $68.62 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $58.32 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $51.58 | 2025 | Rexulti |
| Lundbeck LLC | $39.54 | 2025 | Rexulti |
| Abbott Laboratories | $33.72 | 2023 | Freestyle Libre 2 |
| Philips North America LLC | $31.02 | 2024 | (Ck7) Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $25.28 | 2025 | |
| Daiichi Sankyo INC. | $21.16 | 2024 | Injectafer |
| Pfizer INC. | $19.73 | 2023 | |
| Cequr Corporation | $19.56 | 2024 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $18.00 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.